Last reviewed · How we verify
Metastatic carcinoma to biliary tract — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Imfinzi | durvalumab | AstraZeneca | Programmed Death Ligand-1 Blocker [EPC] | Programmed cell death 1 ligand 1 | 2017-01-01 | |
| Imfinzi | Imfinzi | University Medical Center Groningen | Programmed cell death 1 ligand 1 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- AstraZeneca · 1 drug in Metastatic carcinoma to biliary tract
- University Medical Center Groningen · 1 drug in Metastatic carcinoma to biliary tract
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Metastatic carcinoma to biliary tract:
- Metastatic carcinoma to biliary tract treatment updates — RSS
- Metastatic carcinoma to biliary tract treatment updates — Atom
- Metastatic carcinoma to biliary tract treatment updates — JSON
Cite this brief
Drug Landscape (2026). Metastatic carcinoma to biliary tract — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/metastatic-carcinoma-to-biliary-tract. Accessed 2026-06-10.
Related
- Metastatic carcinoma to biliary tract full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing